Taro Pharmaceutical EPS beats by $0.25, beats on revenue
- Taro Pharmaceutical (NYSE:TARO): Q2 Non-GAAP EPS of $1.09 beats by $0.25; GAAP EPS of -$0.50 misses by $1.34.
- Revenue of $147.1M (+25.1% Y/Y) beats by $9.87M.
- Settlements and loss contingencies of $60.0 million reflect an additional legal contingency provision related to ongoing multi-jurisdiction civil antitrust matters.
- Press Release